ArticleBMC cancer2017

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

Patricia M LoRusso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.